Sur­face On­col­o­gy reins back its lead pro­gram af­ter track­ing low-dose tox­i­c­i­ty for CD47 drug

Sur­face On­col­o­gy’s lead drug — an an­ti-CD47 an­ti­body — has run in­to some heavy tur­bu­lence, and the Cam­bridge, MA-based biotech is buck­ling up for a rough ride …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.